High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer - PubMed (original) (raw)

Review

High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer

Miaomiao Yang et al. Eur J Cancer. 2013 Feb.

Abstract

We synthesised the evidence of microRNAs as prognostic biomarkers in lung cancer. Studies were identified by searching PubMed, Embase and Web of Science until March 2012. Descriptive characteristics for studies were described and an additional meta-analysis for two specific microRNAs (miR-21 and miR-155) which were studied extensively was performed. Pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were calculated. The median study size was 88 patients (interquartile range [IQR]=53-193) and the median HR in the studies that reported statistically significant results was 2.855 (IQR=2.01-5.035). For the studies evaluating miR-21's association with clinical outcomes, the pooled HR suggested that high expression of miR-21 has a negative impact on overall survival (OS) in non-small cell lung cancer (NSCLC) (HR=2.32[1.17-4.62], P<0.05) and recurrence-free survival (RFS)/cancer-specific survival (CSS) in lung adenocarcinoma (HR=2.43[1.67-3.54], P<0.001). As for miR-155, the pooled HR for OS was 2.09 (95%CI: 0.68-6.41, P>0.05) which was not statistically significant, but for RFS/CSS was 1.42 (95% CI: 1.10-1.83, P=0.007). These results indicate that microRNAs show promising associations with prognosis in lung cancer; moreover, specific microRNAs such as miR-21 and miR-155 can predict recurrence and poor survival in NSCLC.

PubMed Disclaimer

Cited by

MicroRNA-155 expression is independently predictive of outcome in chordoma.
Osaka E, Kelly AD, Spentzos D, Choy E, Yang X, Shen JK, Yang P, Mankin HJ, Hornicek FJ, Duan Z. Osaka E, et al. Oncotarget. 2015 Apr 20;6(11):9125-39. doi: 10.18632/oncotarget.3273. Oncotarget. 2015. PMID: 25823817 Free PMC article.
The Role of miR-155 in Antitumor Immunity.
Kalkusova K, Taborska P, Stakheev D, Smrz D. Kalkusova K, et al. Cancers (Basel). 2022 Nov 3;14(21):5414. doi: 10.3390/cancers14215414. Cancers (Basel). 2022. PMID: 36358832 Free PMC article. Review.
Tissue-specific and exosomal miRNAs in lung cancer radiotherapy: from regulatory mechanisms to clinical implications.
Long L, Zhang X, Bai J, Li Y, Wang X, Zhou Y. Long L, et al. Cancer Manag Res. 2019 May 13;11:4413-4424. doi: 10.2147/CMAR.S198966. eCollection 2019. Cancer Manag Res. 2019. PMID: 31191004 Free PMC article. Review.
Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells.
Krstic J, Santibanez JF. Krstic J, et al. ScientificWorldJournal. 2014 Jan 21;2014:521754. doi: 10.1155/2014/521754. eCollection 2014. ScientificWorldJournal. 2014. PMID: 24578639 Free PMC article. Review.
Aberrant expression of miR-21, miR-376c and miR-145 and their target host genes in Merkel cell polyomavirus-positive non-small cell lung cancer.
Lasithiotaki I, Tsitoura E, Koutsopoulos A, Lagoudaki E, Koutoulaki C, Pitsidianakis G, Spandidos DA, Siafakas NM, Sourvinos G, Antoniou KM. Lasithiotaki I, et al. Oncotarget. 2016 Aug 11;8(68):112371-112383. doi: 10.18632/oncotarget.11222. eCollection 2017 Dec 22. Oncotarget. 2016. PMID: 29348831 Free PMC article.

High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer - PubMed (original) (raw)